Navigating the Recent Rheumatoid Arthritis Guidelines to Achieve Disease Remission and Reduce Patient

Access Activity

Overview / Abstract:

Roy M. Fleischmann, MD, discusses the latest evidence for the management of patients with moderate-to-severe rheumatoid arthritis who do not achieve treatment goals with initial disease-modifying anti-rheumatic drug therapy. A key treatment principle emphasized by Dr. Fleischmann is using a treat-to-target approach guided by validated tools for assessing disease activity and patient-reported outcomes. Among the treatment options, Dr. Fleischmann highlights the pharmacology of the latest approved treatments for rheumatoid arthritis. Using case scenarios, he illustrates how they might be integrated with other therapies.

• Epidemiology
• Efficacy of csDMARDs, bDMARDs, and tsDMARDs
• Assessing treatment response
• Treatment principles
• Guideline recommendations
• Key trials of 2nd-line therapy
• Case scenarios


Oct 15, 2021


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Credits / Hours

This activity is supported by an independent educational grant from Sanofi Genzyme.



Presenters / Authors / Faculty

Roy M. Fleischmann, MD
Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Medical Director
Metroplex Clinical Research Center
Dallas, Texas

Activity Specialities / Related Topics

Rheumatology / Arthritis, Primary Care

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Sanofi Genzyme.

Keywords / Search Terms

Annenberg Center for Health Sciences at Eisenhower Rheumatoid Arthritis Guidelines Rheumatoid Arthritis Remission Arthritis Disease remission-arthritis Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map